FDA hits CDMO Ei for making drugs and pesticides with same equipment

fda
The plant, which produces finished pharmaceuticals, was inspected in early October 2017. (FDA)

The FDA hit Ei, a CDMO, with a warning letter for manufacturing pharmaceuticals in the same building and with the same equipment it uses to produce pesticides.

In its letter posted to the regulatory agency’s website, the FDA outlined poor manufacturing procedures at the company’s facility located in Kannapolis, North Carolina. The plant, which produces finished pharmaceuticals like liquid and semisolid topical drugs, was inspected in early October 2017.

The agency said inspectors found the company “manufactured topical human drugs and several pesticides in the same building, using shared equipment” despite the risk of cross contamination. Inspectors also found two of the drugs meant for human use contained a pesticide produced at the facility.

Additionally, the agency said Ei didn’t have or follow correct procedures for cleaning and maintaining the equipment, and failed to investigate any “unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications.”

“Our investigator also found evidence of contamination from unknown impurities in six engineering batches of clobetasol propionate 0.05% topical spray,” the agency wrote. “You produced these drug products using the same equipment and facilities that you use for commercial manufacturing.”

The FDA recommended Ei hire an outside consultant to help them with the issues.

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.